Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Course in the Treatment of Acute Myeloid Leukemia With Venetoclax
The aim of this study is to document all patients with AML who are treated with the BCL2 inhibitor Venetoclax outside a clinical trial in all hospitals participating in this registry study in a standardised manner. Data is collected retrospectively and multi-centric. It is neither a therapy study nor is the therapy influenced by this study. 1. Systematic and uniform collection and documentation of all patients treated with the BCL2 inhibitor Venetoclax. 2. Collection and integrative analysis of clinical data of included patients. 3. Mutation analysis of available patient samples and correlation with clinical parameters.
Study Type
OBSERVATIONAL
Enrollment
100
Registry study observing clinical and biological characteristics of patients with acute myeloid leukemia who are treated with Venetoclax.
Medical School Hannover
Hanover, Lower Saxony, Germany
RECRUITINGOverall response rate of Venetoclax treatment.
Overall response rate of Venetoclax treatment (complete remission, complete remission with incomplete regeneration, partial remission)
Time frame: 4 months
Event-free survival during Venetoclax treatment
Event-free survival of patients with relapsed/refractory AML receiving Venetoclax
Time frame: 5 years
Relapse-free survival during Venetoclax treatment
Relapse-free survival of patients with relapsed/refractory AML receiving Venetoclax
Time frame: 5 years
Overall survival during Venetoclax treatment
Overall survival of patients with relapsed/refractory AML receiving Venetoclax
Time frame: 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.